Clinical Trial Update: Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating camrelizumab in combination with chemotherapy as neoadjuvant therapy for early or locally advanced triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Blokhin's Russian Cancer Research Center | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING